Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 31 (5), 371-4

Medical Castration Using Megestrol Acetate and Minidose Estrogen

Clinical Trial

Medical Castration Using Megestrol Acetate and Minidose Estrogen

D E Johnson et al. Urology.


Sixty-two men who presented with previously untreated metastatic carcinoma of the prostate (D0: 10 patients; D1: 29 patients; D2: 23 patients) received oral megestrol acetate (80 mg twice daily) and minidose estrogen (diethylstibestrol 0.1 mg or ethinyl estradiol 0.05 mg once daily) as a means of achieving total androgen ablation (testicular and adrenal). A high incidence of feminizing side effects (70-74%), a higher than expected rate of cardiovascular complications (18%), an unexpected need for cortisone replacement (13%), and failure of patients with Stage D2 disease to obtain results better than those of standard therapy during the first year of observation suggest this regimen offers no advantage over other more conventional therapy.

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

  • Hormonal Therapy for Stage D Cancer of the Prostate
    MR Gudziak et al. West J Med 160 (4), 351-9. PMID 8023485. - Review
    Adenocarcinoma of the prostate is the most common malignant neoplasm occurring in men. About half of patients present with metastatic disease. The mainstay of the treatme …

Publication types

MeSH terms

LinkOut - more resources